Plans to transfer 100% equity of Tongan Pharmaceutical to continue focusing on the biopharmaceutical track

June 12, 2025  Source: drugdu 49

"/

Kexing Pharmaceuticals(688136) announced on June 11, the company plans to transfer 100% equity of its wholly-owned subsidiary Shenzhen Tongan Pharmaceutical Co., Ltd. for RMB 15 million.To Guangxi Zhuang Autonomous Region Drug Research Institute Co., Ltd. The company's stock closed at 56.39 yuan per share on June 10, up 6.40%.

Guangxi Pharmaceutical Research Institute is a high-tech enterprise dedicated to pharmaceutical research and development and innovation .Enterprise, Guangxi Specialized, Refined, Special and New Enterprise. It has 5 national exclusive varieties and nearly 40 product approvals. Its credit status is good, it has not been listed as a dishonest debtor, and it has the ability to perform its contracts.

Tongan Pharmaceutical's original main business was to produce Kehuang Capsules on behalf of the company. Now the drug has been transferred to the company's own production. In recent years, Tongan Pharmaceutical has not actually carried out business. At present, it mainly holds 19 traditional Chinese medicines such as Vitamin C Yinqiao Tablets.There are a total of 20 drug approval numbers, which are somewhat different from the company's current core business layout. Subsequent business operations will require a longer period of investment and resource allocation.

The announcement stated that the company's sale of Tongan Pharmaceutical's equity will help it continue to focus on the biopharmaceutical track, improve its core competitiveness, reduce operating risks, and is in line with the company's long-term strategic development plan. After the completion of this transaction, it is expected to increase the company's total profit and cash flow in 2025.

Kexing Biotech's main products include human interferon α1b for injection, human erythropoietin injection (CHO cells), human granulocyte-stimulating factor injection, human clostridium butyricum combined live bacteria powder/capsules, human Chinese patent medicine Kehuang capsules, and Segansu Entecavir tablets.

In 2024, the company achieved total operating revenue of 1.407 billion yuan, a year-on-year increase of 11.75%; net profit attributable to shareholders of the parent was 31.4809 million yuan, reversing the loss year-on-year; in the first quarter of 2025, the company achieved total operating revenue of 354 million yuan; net profit attributable to shareholders of the parent was 25.5772 million yuan, a year-on-year increase of 106.21%.

https://finance.eastmoney.com/a/202506113427480154.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.